Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
Adrenocortical carcinoma
Lipoprotein
Mitotane
Pharmacokinetics
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
26
03
2024
accepted:
03
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Mitotane is the only approved treatment for metastatic adrenocortical carcinoma (ACC). Monitoring plasma levels is recommended, but its predictive value is insufficient. This prospective study of the French ENDOCAN-COMETE network aimed to investigate the prognostic role of plasma mitotane levels pharmacokinetics and free or bound to lipoprotein fraction measurements during six consecutive months. Lipoprotein fractions were isolated by ultracentrifugation, and mitotane level was determined by HPLC-UV. Total, free, and lipoprotein fraction bound plasma mitotane were monitored every two months for six months with morphological assessment. The primary endpoint was overall survival (OS). 21 patients with metastatic ACC were included. Median overall survival was 23 months. The median free mitotane level per patient was 12% (± 7%), and the majority (88%) was bound to lipoprotein fractions. Several pharmacokinetics measures of total mitotane were related to OS: first level at one month (p = 0.026), mean level (p = 0.055), and area under the curve (AUC) (p = 0.048), with higher exposure associated to longer OS. Free mitotane (not bounded) and mitotane bounded to lipoprotein subfraction added no prognostic values. The relationship between the mitotane level and OS suggested a minimum "effective" threshold of 10-15 mg/L or an area under the curve above 100 mg/L/month with no individualized maximum value. This prospective study did not identify any added prognostic value of free mitotane level over the total level. Early total mitotane level measurements (before 3-6 months) were related to OS with a higher and faster exposure related to more prolonged survival.
Identifiants
pubmed: 39172357
doi: 10.1007/s40618-024-02439-7
pii: 10.1007/s40618-024-02439-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Libé R, Borget I, Ronchi CL et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol Off J Eur Soc Med Oncol 26:2119–2125. https://doi.org/10.1093/annonc/mdv329
doi: 10.1093/annonc/mdv329
Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 31:1476–1490. https://doi.org/10.1016/j.annonc.2020.08.2099
doi: 10.1016/j.annonc.2020.08.2099
Naing A, Meric-Bernstam F, Stephen B et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347. https://doi.org/10.1136/jitc-2019-000347
doi: 10.1136/jitc-2019-000347
pubmed: 32188704
pmcid: 7078933
Fassnacht M, Dekkers O, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. https://doi.org/10.1530/EJE-18-0608
doi: 10.1530/EJE-18-0608
pubmed: 30325179
pmcid: 6182189
Haak HR, Hermans J, Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951. https://doi.org/10.1038/bjc.1994.183
doi: 10.1038/bjc.1994.183
pubmed: 8180029
pmcid: 1968906
Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392
doi: 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
pubmed: 11745214
Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851. https://doi.org/10.1210/jc.2010-2676
doi: 10.1210/jc.2010-2676
pubmed: 21470991
Megerle F, Herrmann W, Schloetelburg W et al (2018) Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 103:1686–1695. https://doi.org/10.1210/jc.2017-02591
doi: 10.1210/jc.2017-02591
pubmed: 29452402
Reidy-Lagunes DL, Lung B, Untch BR et al (2017) Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug. Oncologist 22:1102–1106. https://doi.org/10.1634/theoncologist.2016-0459
doi: 10.1634/theoncologist.2016-0459
pubmed: 28559412
pmcid: 5599197
Hescot S, Slama A, Lombès A et al (2013) Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 20:371–381. https://doi.org/10.1530/ERC-12-0368
doi: 10.1530/ERC-12-0368
pubmed: 23696597
Sbiera S, Leich E, Liebisch G et al (2015) Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156:3895–3908. https://doi.org/10.1210/en.2015-1367
doi: 10.1210/en.2015-1367
pubmed: 26305886
Slooten H, Moolenaar AJ, Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–53
doi: 10.1016/0277-5379(84)90033-6
pubmed: 6537915
Terzolo M, Baudin AE, Ardito A et al (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169:263–270. https://doi.org/10.1530/EJE-13-0242
doi: 10.1530/EJE-13-0242
pubmed: 23704714
Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17:797–807. https://doi.org/10.1677/ERC-09-0341
doi: 10.1677/ERC-09-0341
pubmed: 20592067
Vezzosi D, Do Cao C, Hescot S et al (2018) Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm Cancer 9:62–69. https://doi.org/10.1007/s12672-017-0313-6
doi: 10.1007/s12672-017-0313-6
pubmed: 29071575
Megerle F, Kroiss M, Hahner S, Fassnacht M (2019) Advanced adrenocortical carcinoma—what to do when first-line therapy fails? Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 127:109–116. https://doi.org/10.1055/a-0715-1946
doi: 10.1055/a-0715-1946
Puglisi S, Calabrese A, Basile V et al (2020) Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers 12:740. https://doi.org/10.3390/cancers12030740
doi: 10.3390/cancers12030740
pubmed: 32245135
pmcid: 7140087
Pohland RC, Counsell RE (1985) The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicol Appl Pharmacol 77:47–57
doi: 10.1016/0041-008X(85)90266-2
pubmed: 3966242
Gebhardt DO, Moolenaar AJ, Seters AP et al (1992) The distribution of o, p’-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemother Pharmacol 29:331–334
doi: 10.1007/BF00685956
pubmed: 1537084
Kroiss M, Plonné D, Kendl S et al (2016) Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 174:343–353. https://doi.org/10.1530/EJE-15-0946
doi: 10.1530/EJE-15-0946
pubmed: 26671975
Hescot S, Seck A, Guerin M et al (2015) Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab 100:2890–2898. https://doi.org/10.1210/JC.2015-2080
doi: 10.1210/JC.2015-2080
pubmed: 26120791
Hescot S, Paci A, Seck A et al (2014) The lack of antitumor effects of o, p’DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer 5:312–323. https://doi.org/10.1007/s12672-014-0189-7
doi: 10.1007/s12672-014-0189-7
pubmed: 25026941
pmcid: 5127823
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
Sauerbrei W, Perperoglou A, Schmid M et al (2020) State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues. Diagn Progn Res 4:3. https://doi.org/10.1186/s41512-020-00074-3
doi: 10.1186/s41512-020-00074-3
pubmed: 32266321
pmcid: 7114804
Bogaerts J, Sydes MR, Keat N et al (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer 51:271–281. https://doi.org/10.1016/j.ejca.2014.10.027
doi: 10.1016/j.ejca.2014.10.027
pubmed: 25542058
pmcid: 4639696
Decker RA, Elson P, Hogan TF et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110:1006–1013
pubmed: 1745969
Williamson SK, Lew D, Miller GJ et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88:1159–1165
doi: 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R
pubmed: 10699907
Baudin E, Endocrine Tumor Board of Gustave Roussy (2015) Adrenocortical carcinoma. Endocrinol Metab Clin North Am 44:411–434. https://doi.org/10.1016/j.ecl.2015.03.001
doi: 10.1016/j.ecl.2015.03.001
pubmed: 26038209
Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197. https://doi.org/10.1056/NEJMoa1200966
doi: 10.1056/NEJMoa1200966
pubmed: 22551107
Wängberg B, Khorram-Manesh A, Jansson S et al (2010) The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17:265–272. https://doi.org/10.1677/ERC-09-0190
doi: 10.1677/ERC-09-0190
pubmed: 20026647
Abraham J, Bakke S, Rutt A et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333–2343. https://doi.org/10.1002/cncr.10487
doi: 10.1002/cncr.10487
pubmed: 12015757
Ayala-Ramirez M, Jasim S, Feng L et al (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169:891–899. https://doi.org/10.1530/EJE-13-0519
doi: 10.1530/EJE-13-0519
pubmed: 24086089
pmcid: 4441210
Puglisi S, Calabrese A, Basile V et al (2019) Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment. J Clin Med 8:1850. https://doi.org/10.3390/jcm8111850
doi: 10.3390/jcm8111850
pubmed: 31684071
pmcid: 6912753
Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891–897. https://doi.org/10.1007/s00268-001-0047-y
doi: 10.1007/s00268-001-0047-y
pubmed: 11572030
Kerkhofs TMA, Verhoeven RHA, Bonjer HJ et al (2013) Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol 169:83–89. https://doi.org/10.1530/EJE-13-0142
doi: 10.1530/EJE-13-0142
pubmed: 23641018
Germano A, Rapa I, Volante M et al (2015) RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Mol Cell Endocrinol 401:105–110. https://doi.org/10.1016/j.mce.2014.11.027
doi: 10.1016/j.mce.2014.11.027
pubmed: 25497672
Altieri B, Sbiera S, Herterich S et al (2020) Effects of germline CYP2W1*6 and CYP2B6*6 single nucleotide polymorphisms on mitotane treatment in adrenocortical carcinoma: a Multicenter ENSAT Study. Cancers 12:359. https://doi.org/10.3390/cancers12020359
doi: 10.3390/cancers12020359
pubmed: 32033200
pmcid: 7072643